Genelux Corporation, a late clinical-stage biotechnology company focused on improving the lives of patients affected by difficult-to-treat solid tumors, announced today it has successfully raised $200.0 million from investors. This substantial capital infusion marks a significant milestone for the company, providing robust financial backing to support its ongoing clinical development and strategic growth initiatives.
At the core of Genelux's approach is its ChoiceTM Discovery Platform, which has generated over 500 versions of the vaccinia virus for oncolytic immunotherapy development. The company's lead product candidate, Olvi-Vec, is currently undergoing a Phase 3 registrational clinical trial for Platinum-Resistant/Refractory Ovarian Cancer (PRROC). Olvi-Vec is also being developed for other indications, including Non-Small Cell Lung Cancer (NSCLC), recurrent Small Cell Lung Cancer (SCLC), and recurrent Ovarian Cancer, highlighting its broad potential.
The $200.0 million in funding underscores investor confidence in Genelux's innovative oncolytic immunotherapy platform and its pipeline of investigational products. The company plans to deploy these funds to accelerate the clinical advancement of Olvi-Vec across its various trials, including the pivotal Phase 3 study, and to further develop its pipeline of next-generation oncolytic immunotherapies. This capital will also support the expansion of research and development efforts aimed at stimulating personalized immune responses for patients with aggressive solid tumor types, reinforcing its commitment to addressing critical unmet needs.
This investment positions Genelux to continue its mission of bringing novel therapeutic options to patients facing challenging cancers. The company remains dedicated to advancing its clinical programs and expanding its scientific capabilities to address unmet medical needs in oncology.
.png&w=3840&q=75)
